VK 5211

Drug Profile

VK 5211

Alternative Names: LGD 4033; VK-5211

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Viking Therapeutics
  • Class Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hip fracture
  • Preclinical Cachexia
  • No development reported Hypogonadism; Muscular atrophy; Osteoporosis

Most Recent Events

  • 28 Nov 2017 Positive top-line efficacy and adverse events data from a phase II trial in Hip fracture released by Viking Therapeutics
  • 12 Jul 2017 Viking Therapeutics completes enrolment in its phase II trial for Hip fracture in USA, Romania, Hungary and Serbia (NCT02578095)
  • 21 Mar 2017 Viking Therapeutics has patent protection and pending patent applications for thyroid hormone receptor beta agonists in USA, Europe, Chile, Argentina, Brazil, Canada, China, India, Japan, Korea, Mexico, Taiwan, and Venezuela
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top